BioNTech will release Q3 2025 financial results on November 3, followed by a conference call for updates.
Quiver AI Summary
BioNTech SE will release its financial results for the third quarter of 2025 on November 3, 2025, and will host a conference call and webcast at 8:00 a.m. EST to discuss these results and provide a corporate update. Interested participants can register to access the call by following a provided link, and it is advised to register at least one day in advance. The company, a leader in next-generation immunotherapy, is focused on developing innovative biopharmaceuticals for cancer and other serious diseases, leveraging its expertise in mRNA technology. BioNTech collaborates with several major pharmaceutical companies to advance its diverse pipeline. Replays of the call will be available on the company’s website for 30 days following the event.
Potential Positives
- BioNTech is scheduled to announce its third-quarter financial results, indicating ongoing business operations and transparency with investors.
- The company will host a conference call and webcast to discuss financial results, promoting direct engagement with investors and stakeholders.
- BioNTech's diverse portfolio includes mRNA cancer immunotherapies and next-generation therapeutics, highlighting its innovative position in the biopharmaceutical industry.
- The establishment of broad relationships with various pharmaceutical collaborators underscores BioNTech's collaborative efforts and potential for future growth.
Potential Negatives
- None
FAQ
When will BioNTech announce its Q3 2025 financial results?
BioNTech will announce its Q3 2025 financial results on November 3, 2025.
How can I access the BioNTech conference call?
You can register for the conference call via the provided link, and dial-in numbers will be sent to you.
What time is the BioNTech conference call scheduled?
The conference call is scheduled for 8:00 a.m. EST (2:00 p.m. CET) on November 3, 2025.
Where can I find the replay of the BioNTech conference call?
The replay of the webcast will be available on BioNTech's website for 30 days after the call.
What is BioNTech's focus as a biopharmaceutical company?
BioNTech focuses on developing novel immunotherapies for cancer and serious diseases using mRNA technology and therapeutic modalities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNTX Congressional Stock Trading
Members of Congress have traded $BNTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BNTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 08/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BNTX Hedge Fund Activity
We have seen 113 institutional investors add shares of $BNTX stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 3,512,318 shares (+4076.8%) to their portfolio in Q2 2025, for an estimated $373,956,497
- VIKING GLOBAL INVESTORS LP removed 879,972 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $93,690,618
- DODGE & COX added 877,437 shares (+inf%) to their portfolio in Q2 2025, for an estimated $93,420,717
- FMR LLC added 875,600 shares (+12.0%) to their portfolio in Q2 2025, for an estimated $93,225,132
- MILLENNIUM MANAGEMENT LLC removed 544,970 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $58,022,955
- BANK OF NEW YORK MELLON CORP added 410,351 shares (+58.8%) to their portfolio in Q2 2025, for an estimated $43,690,070
- BLACKROCK, INC. removed 351,912 shares (-21.1%) from their portfolio in Q2 2025, for an estimated $37,468,070
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BNTX Analyst Ratings
Wall Street analysts have issued reports on $BNTX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- B of A Securities issued a "Buy" rating on 08/05/2025
- Wells Fargo issued a "Overweight" rating on 08/05/2025
- Truist Securities issued a "Buy" rating on 06/03/2025
- Citigroup issued a "Buy" rating on 05/06/2025
To track analyst ratings and price targets for $BNTX, check out Quiver Quantitative's $BNTX forecast page.
$BNTX Price Targets
Multiple analysts have issued price targets for $BNTX recently. We have seen 8 analysts offer price targets for $BNTX in the last 6 months, with a median target of $135.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $120.0 on 10/23/2025
- Terence Flynn from Morgan Stanley set a target price of $131.0 on 10/10/2025
- Robert Burns from HC Wainwright & Co. set a target price of $136.0 on 09/08/2025
- Tazeen Ahmad from B of A Securities set a target price of $134.0 on 08/05/2025
- Mohit Bansal from Wells Fargo set a target price of $150.0 on 08/05/2025
- Asthika Goonewardene from Truist Securities set a target price of $155.0 on 06/03/2025
- Asad Haider from Goldman Sachs set a target price of $110.0 on 05/29/2025
Full Release
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EST (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link . Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link .
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com . A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com .
CONTACTS
Investor Relations
Douglas Maffei, PhD
[email protected]
Media Relations
Jasmina Alatovic
[email protected]
